STAINES-UPON-THAMES, United Kingdom, Aug. 9, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced publication of a new retrospective, claims-based data analysis that highlights a disparity between patients currently being...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]-adverse-events-300693608.html